At EBMT 2025, Yasmina Serroukh from Erasmus MC presented a benchmark study evaluating the role of allogeneic stem cell transplantation (allo-SCT) in follicular lymphoma (FL). The analysis, drawn from a large contemporary cohort, confirms that allo-SCT remains potentially curative for a subset of patients—particularly in CAR-T and bispecific antibody-refractory cases.
Key findings include:
Allo-SCT remains effective despite the associated risk of non-relapse mortality.
Use of haploidentical donors and post-transplant cyclophosphamide (PTCy) is validated in the FL setting.
Outcomes may be influenced by patient age, disease status, and prior autologous SCT.
As advanced therapies evolve, this benchmark underscores that allo-SCT still has an important role in selected FL patients, especially when other options are exhausted.
Kudos to the extensive collaborative effort behind this work, including contributions from Yasmina Serroukh, Ali Bazarbachi, Silvia Montoto, Luca Castagna, and many more experts across Europe.
For more details: https://lnkd.in/ggmHU-fA
